{"id":14951,"date":"2016-10-06T08:52:29","date_gmt":"2016-10-06T06:52:29","guid":{"rendered":"http:\/\/cms.munich-startup.net\/?p=14951"},"modified":"2019-04-18T11:26:14","modified_gmt":"2019-04-18T09:26:14","slug":"40-million-euro-immunotherapy-startup-iomx","status":"publish","type":"post","link":"https:\/\/cms.munich-startup.net\/en\/14951\/40-million-euro-immunotherapy-startup-iomx\/","title":{"rendered":"40 million euros in the first round for immunotherapy startup iOmx"},"content":{"rendered":"

With MPM Capital, Sofinnova Partners, Wellington Partners and Merck<\/span> Ventures was able iOmx Therapeutics AG<\/a> out of Martinsried<\/a> Convince four top investors to invest in a Series A round and raise a record-breaking \u20ac40 million.<\/strong><\/p>\n

iOmx Therapeutics AG was founded by scientists who previously worked in German Cancer Research Center (DKFZ) <\/a>in Heidelberg. The startup specializes in drugs designed to prevent cancer from evading the body's immune system. Speaking to the journal Itranskript published by Biocom Verlag, iOmx CEO Sebastian Meier-Ewer expressed his conviction that they can significantly increase the number of patients who respond to cancer immunotherapies.<\/p>\n

\u201cExceptional management, world-class science and a transformative technology platform\u201d<\/h3>\n

Henrijette Richter<\/strong>, Partner at Sofinnova Partners and Chair of the iOmx Supervisory Board, explains:<\/p>\n

\u201cThe company combines all the core attributes we were looking for: exceptional management, world-class science, and a transformative technology platform with the potential to deliver proprietary, more effective cancer therapeutics.\u201d<\/p><\/blockquote>\n

Ruth Herzog<\/strong>, Head of Technology Transfer at the DKFZ, adds:<\/p>\n

\u201cFor a young company in the life science sector, funding of this amount is a real honor,\u201d<\/p><\/blockquote>\n

and is happy,<\/p>\n

\u201cthat intellectual property from the German Cancer Research Center is receiving such recognition from international investors.\u201d<\/p><\/blockquote>\n<\/div>","protected":false},"excerpt":{"rendered":"

Martinsried-based iOmx Therapeutics AG was able to convince four top investors, MPM Capital, Sofinnova Partners, Wellington Partners, and Merck Ventures, to invest in a Series A round, raising a record-breaking \u20ac40 million. iOmx Therapeutics AG was founded by scientists who previously worked at the German Cancer Research Center (DKFZ) in Heidelberg. \u2026<\/p>","protected":false},"author":26,"featured_media":14957,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5638,1],"tags":[155,371,2068],"acf":[],"yoast_head":"\n40 Mio. Euro in der ersten Runde f\u00fcr Immuntherapie-Startup iOmx - Munich Startup<\/title>\n<meta name=\"description\" content=\"Die iOmx Therapeutics AG aus Martinsried konnte gleich vier Top-Geldgeber von einem rekordverd\u00e4chtigem Investment im Rahmen einer Serie-A-Runde \u00fcberzeugen.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/14951\/40-million-euro-immunotherapy-startup-iomx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"40 Mio. Euro in der ersten Runde f\u00fcr Immuntherapie-Startup iOmx - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Die iOmx Therapeutics AG aus Martinsried konnte gleich vier Top-Geldgeber von einem rekordverd\u00e4chtigem Investment im Rahmen einer Serie-A-Runde \u00fcberzeugen.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/14951\/40-million-euro-immunotherapy-startup-iomx\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-10-06T06:52:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-04-18T09:26:14+00:00\" \/>\n<meta name=\"author\" content=\"Simon Tischer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Simon Tischer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/\",\"url\":\"https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/\",\"name\":\"40 Mio. Euro in der ersten Runde f\u00fcr Immuntherapie-Startup iOmx - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2016\/10\/Dendritische_Zelle.jpg\",\"datePublished\":\"2016-10-06T06:52:29+00:00\",\"dateModified\":\"2019-04-18T09:26:14+00:00\",\"author\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/cab6cd082a88a9e4b2d6ca61a9031a4d\"},\"description\":\"Die iOmx Therapeutics AG aus Martinsried konnte gleich vier Top-Geldgeber von einem rekordverd\u00e4chtigem Investment im Rahmen einer Serie-A-Runde \u00fcberzeugen.\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2016\/10\/Dendritische_Zelle.jpg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2016\/10\/Dendritische_Zelle.jpg\",\"width\":2494,\"height\":1062,\"caption\":\"dendritische Zelle\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"40 Mio. Euro in der ersten Runde f\u00fcr Immuntherapie-Startup iOmx\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/cab6cd082a88a9e4b2d6ca61a9031a4d\",\"name\":\"Simon Tischer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0768e5403c34aa0074a7e723cd3a2795?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0768e5403c34aa0074a7e723cd3a2795?s=96&d=blank&r=g\",\"caption\":\"Simon Tischer\"},\"description\":\"Von Dezember 2015 bis Juni 2023 war Simon Tischer als Redakteur f\u00fcr Munich Startup t\u00e4tig.\",\"url\":\"https:\/\/cms.munich-startup.net\/en\/author\/tischer\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2016\/10\/Dendritische_Zelle.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2494\" \/>\n\t<meta property=\"og:image:height\" content=\"1062\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"40 million euros in the first round for immunotherapy startup iOmx - Munich Startup","description":"iOmx Therapeutics AG from Martinsried was able to convince four top investors of a record-breaking investment in a Series A round.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/14951\/40-million-euro-immunotherapy-startup-iomx\/","og_locale":"en_US","og_type":"article","og_title":"40 Mio. Euro in der ersten Runde f\u00fcr Immuntherapie-Startup iOmx - Munich Startup","og_description":"Die iOmx Therapeutics AG aus Martinsried konnte gleich vier Top-Geldgeber von einem rekordverd\u00e4chtigem Investment im Rahmen einer Serie-A-Runde \u00fcberzeugen.","og_url":"https:\/\/cms.munich-startup.net\/en\/14951\/40-million-euro-immunotherapy-startup-iomx\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_published_time":"2016-10-06T06:52:29+00:00","article_modified_time":"2019-04-18T09:26:14+00:00","author":"Simon Tischer","twitter_card":"summary_large_image","twitter_creator":"@munich_startup","twitter_site":"@munich_startup","twitter_misc":{"Written by":"Simon Tischer","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/","url":"https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/","name":"40 million euros in the first round for immunotherapy startup iOmx - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2016\/10\/Dendritische_Zelle.jpg","datePublished":"2016-10-06T06:52:29+00:00","dateModified":"2019-04-18T09:26:14+00:00","author":{"@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/cab6cd082a88a9e4b2d6ca61a9031a4d"},"description":"iOmx Therapeutics AG from Martinsried was able to convince four top investors of a record-breaking investment in a Series A round.","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2016\/10\/Dendritische_Zelle.jpg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2016\/10\/Dendritische_Zelle.jpg","width":2494,"height":1062,"caption":"dendritische Zelle"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/14951\/40-millionen-euro-immuntherapie-startup-iomx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"40 Mio. Euro in der ersten Runde f\u00fcr Immuntherapie-Startup iOmx"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/cab6cd082a88a9e4b2d6ca61a9031a4d","name":"Simon Tischer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0768e5403c34aa0074a7e723cd3a2795?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0768e5403c34aa0074a7e723cd3a2795?s=96&d=blank&r=g","caption":"Simon Tischer"},"description":"From December 2015 to June 2023, Simon Tischer worked as an editor for Munich Startup.","url":"https:\/\/cms.munich-startup.net\/en\/author\/tischer\/"}]},"og_image":[{"width":2494,"height":1062,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2016\/10\/Dendritische_Zelle.jpg","type":"image\/jpeg"}]},"_showyear":"","_inactive":"","_show_financing":"","_hide_on_map":"","_edit_lock":"1649833851:38","_edit_last":"3","_yoast_wpseo_focuskw":"iOmx","_yoast_wpseo_metadesc":"Die iOmx Therapeutics AG aus Martinsried konnte gleich vier Top-Geldgeber von einem rekordverd\u00e4chtigem Investment im Rahmen einer Serie-A-Runde \u00fcberzeugen.","_yoast_wpseo_linkdex":"71","_thumbnail_id":"14957","wbounce_status":"default","_yoast_wpseo_primary_category":"5638","_yoast_wpseo_focuskw_text_input":"iOmx","_yoast_wpseo_content_score":"60","ms_image_format":"","_ms_image_format":"","ms_dachzeile":"","_ms_dachzeile":"","ms_bump_post_date":"","_ms_bump_post_date":"","guest_author_name":"","_guest_author_name":"","guest_author_image":"","_guest_author_image":"","guest_author_description":"","_guest_author_description":"","ms_post_image_caption":"","_ms_post_image_caption":"","ms_post_image_credit":"","_ms_post_image_credit":"","suppress_startupbox":"","_suppress_startupbox":"","_yoast_wpseo_estimated-reading-time-minutes":"","_wp_old_date":"","_yoast_wpseo_title":"","_yoast_wpseo_wordproof_timestamp":"","footnotes":"","easy_language_simplification_original_id":"","easy_language_source_language":"","easy_language_simplification_language":"","easy_language_api":"","easy_language_prevent_automatic_mode":"","_wp_old_slug":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","easy_language_simplification_state_changed_from":"","easy_language_de_EL_changed":"","ms_competition_deadline":"","_ms_competition_deadline":"","_wpbitly":"","enclosure":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","wbounce_template":"","wbounce_title":"","wbounce_text":"","wbounce_cta":"","wbounce_url":"","wbounce_override":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_oembed_7131efca3705e16bd9da2c41df237660":"","_oembed_time_7131efca3705e16bd9da2c41df237660":"","_pprredirect_type":"","_pprredirect_url":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":"","_newsletterglue":"","easy_language_text_language":"","_wp_desired_post_slug":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/14951"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=14951"}],"version-history":[{"count":0,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/14951\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/14957"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=14951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/categories?post=14951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=14951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}